Sign in

Lou Kerman

Research Analyst at Baird

No verifiable public information could be found about Lou Kerman serving as an analyst at Baird. A thorough search produced no credible evidence of their professional background, company coverage, published research, or analyst performance metrics. There are no LinkedIn profiles, industry rankings, or regulatory records corresponding to an equity analyst named Lou Kerman at Baird. It is possible this individual does not hold the position described or does not have a public professional profile available.

Lou Kerman's questions to Alkermes (ALKS) leadership

Question · Q3 2025

Lou Kerman inquired about the timeline for sharing phase 1 data from AUX4510 and first-in-human data for AUX7290 next year, and the possibility of new data on the low-salt oxybate program from Avadel Pharmaceuticals next year.

Answer

Richard Pops, CEO, stated that completion of SADMAD for AUX4510 and AUX7290 will signal movement into patient-focused studies, with readout timing to be disclosed later. He confirmed strong interest in Avadel's no-salt once-daily program and will provide more details on its development post-acquisition.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts